Coronavirus Update - 14th October 2020

Despite the recent rises in Covid-19 cases throughout the UK and Europe, Arcinova remains open for business at full capacity as we have done throughout this pandemic. As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Webinars from the Arcinova team

About this Event

In this recorded webinar you can join experts from both Arcinova and Covance discussing their insights in and exploring new approaches for optimizing ADME/hAME studies.

Key topics covered are:

  • Why are ADME/human AME (hAME) studies required?
  • What are the regulatory requirements?
  • What are the pharmacy and radiosynthesis challenges?
  • What are the benefits to using an integrated preclinical to clinical approach?

After the panel discussion, the speakers were available to answer questions and provide practical advice; the recording also covers these discussions.

Format and Panelists

The session was be moderated by John Hedley, European Head of Sales - Non-Clinical Development at Covance, and the panelists included:
- John Kendrick | Director, Science & Commercial Strategy for Metabolism & Environmentalism | Covance
- Catherine Laing | Associate Scientific Director for Medical & Scientific Affairs | Clinical Pharmacology Services | Covance
- Eleanor Row | Head of Client Services | Arcinova

Speakers at the webinar

Please click the image below to view the webinar

Covance Arcinova Symposium

Whitepaper

A whitepaper was also created following ths event - please click here for further details